Significant Publications on Infectious Diseases Pharmacotherapy in 2024
Open Access
- 11 December 2025
- journal article
- review article
- Published by SAGE Publications in Journal of Pharmacy Practice
- Vol. 39 (4) , 257-270
Abstract
Purpose: To provide a summarization of the most significant infectious diseases (ID) pharmacotherapy articles published in peer-reviewed literature in 2024. Summary: Members of the Houston Infectious Diseases Network (HIDN) nominated notable articles providing significant contributions to ID pharmacotherapy in 2024. Article nominations included those pertaining to general ID and human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) pharmacotherapy in 2024. To aid selection of the most significant articles in 2024, a survey was created and distributed to members of the Society of Infectious Diseases Pharmacists (SIDP). Out of the 21 total articles nominated by HIDN/SIDP members, 19 pertained to general ID pharmacotherapy, and 2 had pertained to HIV/AIDS pharmacotherapy. Of the SIDP members who participated in the survey, 185 voted for the top 10 general ID pharmacotherapy articles and 46 votes were recorded for the top HIV/AIDS article. The most notable publications are summarized. Conclusion: This review provides a summary of the most recently published ID literature with aims to update clinicians on the current potential practice changing ID pharmacotherapy publications from 2024.Keywords
This publication has 87 references indexed in Scilit:
- Biomarker-Guided Antibiotic Duration for Hospitalized Patients With Suspected SepsisJAMA, 2025
- Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With SepsisJAMA, 2024
- Stewardship Prompts to Improve Antibiotic Selection for Urinary Tract InfectionJAMA, 2024
- Stewardship Prompts to Improve Antibiotic Selection for PneumoniaJAMA, 2024
- HIV Preexposure Prophylaxis With Emtricitabine and Tenofovir Disoproxil Fumarate Among Cisgender WomenJAMA, 2024
- Effect of C-Reactive Protein–Guided Antibiotic Treatment Duration, 7-Day Treatment, or 14-Day Treatment on 30-Day Clinical Failure Rate in Patients With Uncomplicated Gram-Negative BacteremiaJAMA, 2020
- Overuse of Broad-Spectrum Antibiotics for PneumoniaJAMA Internal Medicine, 2020
- Association of 30-Day Mortality With Oral Step-Down vs Continued Intravenous Therapy in Patients Hospitalized With Enterobacteriaceae BacteremiaJAMA Internal Medicine, 2019
- The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)JAMA, 2016
- Clinical Management ofStaphylococcus aureusBacteremiaJAMA, 2014